Duchenne Muscular Dystrophy

PTC Therapeutics Drug Doesn't Meet Goal in Duchenne Trial
Bloomberg
Fri, 10/16/15 - 06:59 am
PTC Therapeutics
Duchenne Muscular Dystrophy
clinical trials
Translarna
FDA ‘Weirdness?’ Separate meetings for BioMarin and Sarepta DMD drugs
Pharmalot
Thu, 10/15/15 - 03:59 pm
FDA
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
​Sarepta’s competitor on Duchenne drug could get a two-month head start on sales
Bizjournals.com
Wed, 10/14/15 - 02:23 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biomarin
eteplirsen
drisapersen
Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?
Motley Fool
Tue, 10/6/15 - 07:13 pm
Sarepta Therapeutics
Biomarin
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
Sarepta's Less-Than-Perfect Data
Motley Fool
Mon, 10/5/15 - 11:56 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Sarepta gets creative in bolstering its case for quick eteplirsen approval
Fierce Biotech
Thu, 10/1/15 - 09:24 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
​Redemption for the drug biz could come next week from Cambridge-based Sarepta
Bizjournals.com
Sun, 09/27/15 - 08:32 pm
Sarepta Therapeutics
eteplirsen
Duchenne Muscular Dystrophy
Sarepta snags priority review status to keep pace with BioMarin in DMD race
Fierce Biotech
Wed, 08/26/15 - 09:28 am
Sarepta Therapeutics
priority review
Duchenne Muscular Dystrophy
FDA
eteplirsen
drisapersen
Biomarin
Sarepta, Biomarin vie for DMD approval, priority review voucher
BioPharma Dive
Mon, 08/24/15 - 11:47 am
Sarepta
Biomarin
Duchenne Muscular Dystrophy
FDA
priority review
review vouchers
BioMarin's Big Bet on Muscular Dystrophy Is Already Paying Off
Motley Fool
Sat, 08/22/15 - 09:01 am
Biomarin
Duchenne Muscular Dystrophy
drisapersen
BioMarin outlines its R&D game plan as Duchenne MD decision nears
Fierce Biotech
Tue, 08/4/15 - 05:51 pm
Biomarin
R&D
Duchenne Muscular Dystrophy
drisapersen
FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs
TheStreet.com
Mon, 07/20/15 - 02:37 pm
FDA
Biomarin
advisory panels
eteplirsen
Sarepta Therapeutics
drisapersen
Duchenne Muscular Dystrophy
Sarepta Therapeutics One Step Closer to Drug Approval
Investopedia
Fri, 07/3/15 - 08:00 pm
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
eteplirsen
Sarepta Submits DMD Drug for FDA Approval Review
TheStreet.com
Mon, 06/29/15 - 10:48 am
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
FDA finally responds to demand for Duchenne Muscular Dystrophy guidance
BioPharma Dive
Wed, 06/10/15 - 10:58 am
FDA
Duchenne Muscular Dystrophy
Saretpa
PTC Therapeutics
Pfizer
Biomarin
FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!
TheStreet.com
Tue, 05/19/15 - 05:02 pm
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
eteplirsen
Why BioMarin’s New Drug Application is Good News for Sarepta Therapuetics
Fierce Pharma Marketing
Wed, 05/6/15 - 11:44 am
Biomarin
Sarepta Therapeutics
drisapersen
Duchenne Muscular Dystrophy
Santhera May Market Muscular Dystrophy Drug on its Own in U.S.
Bloomberg
Wed, 04/15/15 - 09:01 am
Santhera
Duchenne Muscular Dystrophy
Catena
Summit pulls off a downsized IPO for its DMD drug
Fierce Biotech
Thu, 03/5/15 - 08:55 am
Duchenne Muscular Dystrophy
Summit Therapeutics
SMT C1100
IPOs
8 Biotech Stock Controversies Emerging From 'JPM15' Conference
TheStreet.com
Tue, 01/20/15 - 11:33 am
JPMHC 2015
drug pricing
CAR-T
biotech
Gilead Sciences
immuno-oncology
Duchenne Muscular Dystrophy

Pages